Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.
暂无分享,去创建一个
[1] S. Elledge,et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. , 2000, Science.
[2] S. Lowe,et al. Apoptosis in cancer. , 2000, Carcinogenesis.
[3] T. Halazonetis,et al. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. , 2000, Genes & development.
[4] Y Taya,et al. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.
[5] K. Isselbacher,et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. , 1999, Science.
[6] E. Stavridi,et al. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[7] T. Halazonetis,et al. Many faces of ATM: eighth international workshop on ataxia-telangiectasia. , 1999, Biochimica et biophysica acta.
[8] R. Ferl,et al. Specific Interactions with TBP and TFIIB in Vitro Suggest That 14-3-3 Proteins May Participate in the Regulation of Transcription When Part of a DNA Binding Complex , 1999, Plant Cell.
[9] T. Unger,et al. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 , 1999, The EMBO journal.
[10] S. Elledge,et al. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.
[11] R. Mcinnes,et al. Association of the TLX-2 Homeodomain and 14-3-3η Signaling Proteins* , 1998, The Journal of Biological Chemistry.
[12] E. Stavridi,et al. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins , 1998, Nature Genetics.
[13] R. Quatrano,et al. 14-3-3 Proteins Are Part of an Abscisic Acid–VIVIPAROUS1 (VP1) Response Complex in the Em Promoter and Interact with VP1 and EmBP1 , 1998, Plant Cell.
[14] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[15] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[16] T. Jacks,et al. Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption , 1998, Molecular and Cellular Biology.
[17] I. Garkavtsev,et al. The candidate tumour suppressor p33ING1cooperates with p53 in cell growth control , 1998, Nature.
[18] G. Wilson,et al. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma , 1997, The British journal of surgery.
[19] Yoichi Taya,et al. DNA Damage-Induced Phosphorylation of p53 Alleviates Inhibition by MDM2 , 1997, Cell.
[20] M. Laiho,et al. p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle , 1997, Molecular and cellular biology.
[21] G. Stark,et al. The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate , 1997, Oncogene.
[22] Stephen N. Jones,et al. Regulation of p53 stability by Mdm2 , 1997, Nature.
[23] M. Oren,et al. Mdm2 promotes the rapid degradation of p53 , 1997, Nature.
[24] M. Herlyn,et al. Adenovirus infection enhances killing of melanoma cells by a mitotoxin. , 1997, Cancer research.
[25] G. Wahl,et al. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. , 1997, Cancer research.
[26] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[27] K. Ang,et al. Radiation therapy for malignant melanoma. , 1996, The Surgical clinics of North America.
[28] J. Jenrette. Malignant melanoma: the role of radiation therapy revisited. , 1996, Seminars in oncology.
[29] I. Garkavtsev,et al. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation , 1996, Nature Genetics.
[30] C. Thompson,et al. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. , 1996, Genes & development.
[31] C. Kitanaka,et al. Apoptosis in cancer. , 1996, Human cell.
[32] T. Taniguchi,et al. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage , 1996, Nature.
[33] W. El-Deiry,et al. In vitro evaluation of a p53‐expressing adenovirus as an anti‐cancer drug , 1996, International journal of cancer.
[34] D A Scudiero,et al. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines. , 1996, Cancer research.
[35] T. Halazonetis,et al. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. , 1996, Cancer research.
[36] F. Zindy,et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.
[37] L. Sandkuijl,et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds , 1995, Nature Genetics.
[38] A. Gown,et al. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[39] U. Ringborg,et al. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma , 1995, Melanoma research.
[40] Carissa A. Sanchez,et al. A p53-dependent mouse spindle checkpoint , 1995, Science.
[41] P. Workman. To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo? , 1995, Human & experimental toxicology.
[42] K. Arden,et al. Mutation and expression of TP53 in malignant melanomas. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[43] D. Housman,et al. p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.
[44] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[45] M. Skolnick,et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.
[46] D. Fisher. Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.
[47] X. Montano,et al. Analysis of p53 in human cutaneous melanoma cell lines. , 1994, Oncogene.
[48] P. Kleihues,et al. Absence of p53 gene mutations in cutaneous melanoma. , 1994, The Journal of investigative dermatology.
[49] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[50] N. Hayward,et al. Mutation and expression of the p53 gene in human malignant melanoma , 1994, Melanoma research.
[51] J. Nesland,et al. TP53 allele loss, mutations and expression in malignant melanoma. , 1994, British Journal of Cancer.
[52] J. Giorgi,et al. Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. , 1994, Cytometry.
[53] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[54] A. Sober,et al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma , 1993, International journal of cancer.
[55] D. Lane,et al. What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .
[56] W. Cavenee,et al. Mutation and expression of the p53 gene in malignant melanoma cell lines , 1993, International journal of cancer.
[57] D. Barnes,et al. p53 immunoreactivity in human malignant melanoma and dysplastic naevi , 1993, The British journal of dermatology.
[58] N. Lassam,et al. Overexpression of p53 is a late event in the development of malignant melanoma. , 1993, Cancer research.
[59] M. Melamed,et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. , 1993, Leukemia.
[60] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[61] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[62] Scott W. Lowe,et al. p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.
[63] B. Vogelstein,et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.
[64] M. Kastan,et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[65] B. Vogelstein,et al. Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.
[66] U. Schlegel,et al. Mutational analysis of the human p53 gene in malignant melanoma. , 1991, Pigment cell research.
[67] P. Nowell,et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. , 1985, Cancer research.
[68] W. Maltzman,et al. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.